Engineered Bioprocess Converts CO2 Into Amino Acids at 97 Percent Efficiency

Key Takeaways

• 97% CO2-to-amino-acid conversion, highest reported efficiency
• Process cuts bioprocessing costs by 42% via THF recycling
• Heat‑loving enzymes from Moorella thermoacetica enable system purification
• Cell‑free platform eliminates wasteful cellular debris, boosting yield
• Scalable, carbon‑negative method could reshape amino‑acid manufacturing

Summary

Georgia Tech researchers have unveiled a cell‑free biocatalytic platform that converts carbon dioxide into the amino acids serine and glycine with a 97% yield, the highest efficiency reported for any synthetic‑biology system. By introducing heat‑tolerant enzymes from Moorella thermoacetica and thermally denaturing residual cellular components, the team eliminated wasteful side reactions. A five‑fold reduction in the costly cofactor tetrahydrofolate (THF) cuts overall process expenses by 42%. The carbon‑negative, cost‑effective method is positioned for industrial scaling across pharma, feed and chemical sectors.

Pulse Analysis

Traditional amino‑acid manufacturing relies on energy‑intensive fermentation or chemical synthesis, processes that emit large quantities of CO₂ and consume scarce resources. As demand for these building blocks rises in pharmaceuticals, animal feed, and specialty chemicals, the industry faces pressure to decarbonize and improve cost structures. Sustainable alternatives have emerged, yet most struggle to achieve both high conversion efficiency and economic viability, limiting their readiness for large‑scale deployment.

The Georgia Tech team addressed these hurdles by engineering a cell‑free system that leverages thermophilic enzymes from Moorella thermoacetica. Heating the reaction mixture denatures extraneous cellular fragments, while the robust enzymes remain active, driving a near‑quantitative conversion of CO₂ into serine and glycine. Simultaneously, the researchers instituted a closed‑loop THF recycling scheme, slashing cofactor consumption five‑fold and delivering a 42% reduction in overall process costs. This dual focus on yield and expense marks a decisive step toward commercial feasibility, positioning the technology as a viable competitor to conventional routes.

If scaled successfully, the platform could redefine amino‑acid supply chains by delivering a carbon‑negative product at competitive prices. Industries ranging from drug manufacturing to animal nutrition stand to benefit from reduced carbon footprints and lower raw‑material costs. Moreover, the cell‑free architecture simplifies regulatory approval and eases integration with existing bioprocessing infrastructure. Continued optimization and pilot‑plant trials will be critical, but the current results suggest a near‑term pathway for greener, more economical amino‑acid production worldwide.